CLINICAL RESEARCH

EMSCO provides services including review of trial design, medical writing, support with essential clinical trial documents, contracts, publications, management and coordination of clinical trials and other projects associated with MDS. EMSCO’s multilingual staff has ample experience in the international context and is therefore apt to fulfil these tasks.

One of the major goals of EMSCO is to offer an expert MDS office team to assist, design and review clinical trials in MDS. The group offers full-service Sponsor responsibilities across Europe with KOLs in the participating countries to take over CPI roles and experienced staff for comprehensive trial management tasks. Within this environment we aim to improve the quality and comparability of clinical trials in MDS.

EMSCO TRIALS:

Recruitment ongoing:

BERGAMO TRIAL (NCT03824080)

A phase II study evaluating the efficacy and safety of Bemcentinib in patients with MDS or AML failing standard of care therapy
Status: recruiting in France and Germany

PALOMA TRIAL (NCT04061239)

Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML
Status: recruiting in Germany

Recruitment closed:

EUROPE TRIAL (NCT02335268)

Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia
Status: recruitment completed

DACOTA TRIAL (NCT02214407)

Randomized Phase III study of Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML)
Status: recruitment completed

SINTRA-REV TRIAL (NCT01243476)

Multicenter, randomized, double-blind, phase III study of Revlimid® (Lenalidomide) versus Placebo in patients with low risk myelodysplastic syndrome (low and intermediate-1 IPSS) with alteration in 5q and anemia without the need of transfusion
Status: recruitment completed

Closed trials:

SAMBA TRIAL (NCT02992860)

Single agent JNJ-56022473 in MDS and AML patients failing hypomethylating agent based therapy
Status: prematurely terminated